News Center
Good news frequently arrives | Livzon Group's clinical trial application for injectable JP-1366 has been accepted by the National Medical Products Administration's Drug Evaluation Center.
Release time:
2024-12-09
Research and innovation are the development genes of Livzon Group, continuously delving deep, bringing frequent good news.Recently, the new generation developed by Livzon GroupP-CABacid suppressants-for injectionJP-1366clinical trial application has been accepted by the National Medical Products Administration's Drug Evaluation Center. For injectionJP-1366is a potassium ion competitive acid blocker (P-CAB) independently developed by Livzon Group with independent intellectual property rights. Currently, there are no related injectable products on the market in China.
for injectionJP-1366The clinical indications planned for development are bleeding peptic ulcers.JP-1366Its active compound,reversibly inhibits the acid secretion function of the proton pump by binding to the H+/K+-ATPase binding site, thereby producing a strong effect in suppressing gastric acid secretion.Currently, all approved injectable solutions for acid-related diseases that are used for bleeding or are unsuitable for oral administration are traditional proton pump(PPIs) formulations. Compared to traditional
formulations, the injectableis expected to take effect faster, and the first dose is fully effective, with good acid suppression effects at night.In addition, the injectable JP-1366 also has the characteristics of being unaffected by CYP2C19 gene polymorphisms and having small inter-individual variability, making it suitable for the treatment of acid-related diseases.is expected to take effect faster, and the first dose is fully effective, with good acid suppression effects at night.The "Consensus of Experts on Gastroesophageal Reflux Disease in China" has listedJP-1366oral formulations as one of the first-choice drugs for reflux esophagitis. The application scenarios of injectable formulations in clinical practice differ from those of oral formulations, as they are more often used in surgeries, hospitalizations, and other situations. With the upgrading of market demand, more and more experts and patients recognizeP-CAB
class drugs, which are expected to become mainstream acid suppressants in the future, with broad replacement potential.2020Innovation is a must-answer question for Livzon Group's commitment to the life and health industry. In the journey of exploring innovation, Livzon Group adheres to independent research and developmentP-CAB+BDdual-wheel drive, fully leveraging its own R&D advantages, continuously enhancing competitiveness in core areas, and ensuring that more safe, reliable, and effective products safeguard everyone's health.类药物，在未来它有希望成为主流的抑酸药物，替代空间广阔。
创新是丽珠集团致力于生命健康产业的必答题。在探索创新的征程中，丽珠集团坚持自主研发+BD双轮驱动，充分发挥自身研发优势，不断增强核心领域的竞争力，让更多安全可靠、疗效确切的产品为大家的健康保驾护航。
Related Information